Cargando…
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
Richter syndrome (RS) refers to transformation of chronic lymphocytic leukemia (CLL) to an aggressive lymphoma, most commonly diffuse large B-cell lymphoma. RS is known to be associated with a number of genetic alterations such as TP53 and NOTCH1 mutations. However, it is unclear what immune microen...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110984/ https://www.ncbi.nlm.nih.gov/pubmed/33972504 http://dx.doi.org/10.1038/s41408-021-00477-5 |
_version_ | 1783690405765709824 |
---|---|
author | Wang, Yucai Sinha, Sutapa Wellik, Linda E. Secreto, Charla R. Rech, Karen L. Call, Timothy G. Parikh, Sameer A. Kenderian, Saad S. Muchtar, Eli Hayman, Suzanne R. Koehler, Amber B. Van Dyke, Daniel L. Leis, Jose F. Slager, Susan L. Dong, Haidong Kay, Neil E. He, Rong Ding, Wei |
author_facet | Wang, Yucai Sinha, Sutapa Wellik, Linda E. Secreto, Charla R. Rech, Karen L. Call, Timothy G. Parikh, Sameer A. Kenderian, Saad S. Muchtar, Eli Hayman, Suzanne R. Koehler, Amber B. Van Dyke, Daniel L. Leis, Jose F. Slager, Susan L. Dong, Haidong Kay, Neil E. He, Rong Ding, Wei |
author_sort | Wang, Yucai |
collection | PubMed |
description | Richter syndrome (RS) refers to transformation of chronic lymphocytic leukemia (CLL) to an aggressive lymphoma, most commonly diffuse large B-cell lymphoma. RS is known to be associated with a number of genetic alterations such as TP53 and NOTCH1 mutations. However, it is unclear what immune microenvironment changes are associated with RS. In this study, we analyzed expression of immune checkpoint molecules and infiltration of immune cells in nodal samples, and peripheral blood T-cell diversity in 33 CLL and 37 RS patients. Compared to CLL, RS nodal tissue had higher PD-L1 expression in histiocytes and dendritic cells (median 16.6% vs. 2.8%, P < 0.01) and PD1 expression in neoplastic B cells (median 26.0% vs. 6.2%, P < 0.01), and higher infiltration of FOXP3-positive T cells (median 1.7% vs. 0.4%, P < 0.01) and CD163-positive macrophages (median 23.4% vs. 9.1%, P < 0.01). In addition, peripheral blood T-cell receptor clonality was significantly lower in RS vs. CLL patients (median [25th–75th], 0.107 [0.070–0.209] vs. 0.233 [0.111–0.406], P = 0.046), suggesting that T cells in RS patients were significantly more diverse than in CLL patients. Collectively these data suggest that CLL and RS have distinct immune signatures. Better understanding of the immune microenvironment is essential to improve immunotherapy efficacy in CLL and RS. |
format | Online Article Text |
id | pubmed-8110984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81109842021-05-12 Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome Wang, Yucai Sinha, Sutapa Wellik, Linda E. Secreto, Charla R. Rech, Karen L. Call, Timothy G. Parikh, Sameer A. Kenderian, Saad S. Muchtar, Eli Hayman, Suzanne R. Koehler, Amber B. Van Dyke, Daniel L. Leis, Jose F. Slager, Susan L. Dong, Haidong Kay, Neil E. He, Rong Ding, Wei Blood Cancer J Article Richter syndrome (RS) refers to transformation of chronic lymphocytic leukemia (CLL) to an aggressive lymphoma, most commonly diffuse large B-cell lymphoma. RS is known to be associated with a number of genetic alterations such as TP53 and NOTCH1 mutations. However, it is unclear what immune microenvironment changes are associated with RS. In this study, we analyzed expression of immune checkpoint molecules and infiltration of immune cells in nodal samples, and peripheral blood T-cell diversity in 33 CLL and 37 RS patients. Compared to CLL, RS nodal tissue had higher PD-L1 expression in histiocytes and dendritic cells (median 16.6% vs. 2.8%, P < 0.01) and PD1 expression in neoplastic B cells (median 26.0% vs. 6.2%, P < 0.01), and higher infiltration of FOXP3-positive T cells (median 1.7% vs. 0.4%, P < 0.01) and CD163-positive macrophages (median 23.4% vs. 9.1%, P < 0.01). In addition, peripheral blood T-cell receptor clonality was significantly lower in RS vs. CLL patients (median [25th–75th], 0.107 [0.070–0.209] vs. 0.233 [0.111–0.406], P = 0.046), suggesting that T cells in RS patients were significantly more diverse than in CLL patients. Collectively these data suggest that CLL and RS have distinct immune signatures. Better understanding of the immune microenvironment is essential to improve immunotherapy efficacy in CLL and RS. Nature Publishing Group UK 2021-05-10 /pmc/articles/PMC8110984/ /pubmed/33972504 http://dx.doi.org/10.1038/s41408-021-00477-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Wang, Yucai Sinha, Sutapa Wellik, Linda E. Secreto, Charla R. Rech, Karen L. Call, Timothy G. Parikh, Sameer A. Kenderian, Saad S. Muchtar, Eli Hayman, Suzanne R. Koehler, Amber B. Van Dyke, Daniel L. Leis, Jose F. Slager, Susan L. Dong, Haidong Kay, Neil E. He, Rong Ding, Wei Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome |
title | Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome |
title_full | Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome |
title_fullStr | Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome |
title_full_unstemmed | Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome |
title_short | Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome |
title_sort | distinct immune signatures in chronic lymphocytic leukemia and richter syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110984/ https://www.ncbi.nlm.nih.gov/pubmed/33972504 http://dx.doi.org/10.1038/s41408-021-00477-5 |
work_keys_str_mv | AT wangyucai distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT sinhasutapa distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT welliklindae distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT secretocharlar distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT rechkarenl distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT calltimothyg distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT parikhsameera distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT kenderiansaads distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT muchtareli distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT haymansuzanner distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT koehleramberb distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT vandykedaniell distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT leisjosef distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT slagersusanl distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT donghaidong distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT kayneile distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT herong distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome AT dingwei distinctimmunesignaturesinchroniclymphocyticleukemiaandrichtersyndrome |